The agent represents a new class of agents called small modular immunopharmaceuticals. Called CD37-SMIP, the agent targets a protein called CD37 on the surface of these leukemia cells.
The study shows that the agent can successfully attach to the protein on the leukemia cells and kill them. The agent works both by triggering the cells' self-destruction and by causing a particular class of immune cells to attack them.
In an animal model, the agent worked equally as well as the drug rituximab, now routinely used to treat chronic lymphocytic leukemia (CLL) patients. Rituximab targets a different protein on leukemia cells.
The study by researchers at the Ohio State University Comprehensive Cancer Center was published online in the journal Blood.
“Our findings have significant implications for the treatment of CLL and related malignancies,” says principal investigator John C. Byrd, director of the hematologic malignancies program at Ohio State 's James Cancer Hospital and Solove Research Institute.
Overall, Byrd says, “the findings indicate that this could be an effective agent for treating CLL and other malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia when they have expression of the CD37 protein.”
The laboratory portion of the study used CLL cells from patients, laboratory-grown non-Hodgkin's lymphoma cells and acute lymphocytic leukemia cells.
This research showed that the agent kills leukemia cells directly by triggering their self-destruction through the process of apoptosis.
The study also found that this self-destruction happens differently from how other drugs cause apoptosis. Most drugs cause cells to self-destruct by triggering a cell mechanism that requires enzymes called caspases. This new agent, however, works through a mechanism that does not require caspases.
“This is exciting because it means that this agent may benefit patients who are resistant to other CLL drugs,” says co-author Natarajan Muthusamy, a research scientist with Ohio State's Comprehensive Cancer Center. “It also suggests that it might work well in combination with other drugs, as well as alone.”
The findings also show that after the agent binds with the cancer cells, it attracts immune cells called natural killer cells, which also destroy the leukemia cells. Funding from the National Cancer Institute, the Leukemia and Lymphoma Society and the D. Warren Brown Foundation supported this research.
Trubion Pharmaceuticals, Inc., developed CD37-SMIP and provided the drug used in the study. Byrd has received no financial compensation from Trubion.
Darrell E. Ward | EurekAlert!
Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory
How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
24.03.2017 | Materials Sciences
24.03.2017 | Physics and Astronomy
24.03.2017 | Physics and Astronomy